Events

SHERIDAN, WYOMING – May 7, 2025 – Olympus Corporation, a global MedTech leader, has announced its most successful "Dress in Blue" campaign yet, marking a new milestone in its commitment to Colorectal Cancer Awareness Month. With 6,810 employees from across the globe participating, this year’s campaign underscores Olympus’ ongoing dedication to reducing cancer-related deaths through awareness and early detection initiatives.

Record Participation in Global Campaign

This year, Olympus achieved an all-time high participation rate in the company-wide campaign, with employees joining from various regions, including Japan, the Americas, EMEA (Europe, Middle East, and Africa), APAC (Asia-Pacific), and China. For the third consecutive year, the "Dress in Blue" campaign encouraged Olympus employees to wear blue, the color of colorectal cancer awareness, as a show of solidarity and support for the cause.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE:BAX), a global leader in medical technologies, has announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. This dividend is payable on July 1, 2025, to shareholders of record as of May 30, 2025. The indicated annual dividend rate is set at $0.68 per share.

Strategic Commitment to Shareholders

As part of its ongoing commitment to delivering value to its shareholders, Baxter continues to maintain a strong dividend policy. The company’s decision to declare this quarterly cash dividend reflects both the stability of its financial performance and its dedication to providing consistent returns to its investors.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a leading global medtech company, has announced its first-quarter financial results for 2025, reflecting solid performance driven by strategic transformation initiatives. The company’s results indicate continued growth across its core business segments, positioning Baxter for long-term value creation despite global macroeconomic uncertainty.

Strategic Transformation and Focus on Execution

"Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey," said Brent Shafer, chair and interim CEO of Baxter. "Baxter today is a more focused and agile organization, well-positioned to drive enhanced value for patients, healthcare providers, customers, and shareholders through our reinvigorated emphasis on execution, innovation, and profitable growth."

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a global leader in medical technology, will host a conference call on Thursday, May 8, 2025, at 7:30 a.m. Central Time to discuss its first-quarter 2025 financial results. Investors, analysts, and other stakeholders are invited to participate in the call by pre-registering through the provided link to receive the necessary call-in information.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc., a global leader in advancing surgical innovation, has announced the launch of its Hemopatch Sealing Hemostat with room temperature storage at a symposium in Vienna, Austria. This new product evolution significantly improves accessibility for surgeons, offering a practical and effective solution for controlling bleeding and preventing leakage during surgery. The product is now available for order throughout Europe, marking a key step forward in Baxter’s ongoing commitment to enhancing patient care.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, will announce its operating results for the first quarter ending March 31, 2025, after market close on Wednesday, April 23, 2025. The company will then host a conference call at 5:00 p.m. ET that same day to discuss these results in detail, providing insights into its financial performance and future strategic direction.

Conference Call Details and Participation

Edwards Lifesciences invites all interested parties to join the conference call. To participate, dial (877) 704-2848 or (201) 389-0893. For those unable to attend live, the conference call will be available for replay on the "Investor Relations" section of the Edwards website at ir.edwards.com.

About Edwards Lifesciences

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) today unveiled new eight-year clinical data, confirming the exceptional long-term performance of its RESILIA tissue technology in aortic surgical valves. The data demonstrate significant improvements in patient outcomes, reinforcing the company's leadership in structural heart solutions.

The new findings, presented at the Heart Valve Society Annual Meeting, provide compelling evidence that patients receiving aortic surgical valves with RESILIA tissue experienced significantly better long-term outcomes compared to those with non-RESILIA tissue valves. These results highlight the value of Edwards’ innovation in delivering superior durability and performance, crucial for improving patient care and reducing the need for reoperations.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, has announced its financial results for the first quarter ended March 31, 2025. The company delivered impressive growth across key product categories, including Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), positioning itself for continued success in the structural heart market.

Strong Sales Growth Drives First Quarter Results

In Q1 2025, Edwards Lifesciences reported total sales of $1.41 billion, reflecting a robust 6.2% increase year-over-year, or 7.9% on an adjusted basis. The company also posted a solid earnings per share (EPS) of $0.622, with adjusted EPS of $0.64, reinforcing its strong financial position.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced the U.S. Food and Drug Administration (FDA) approval of its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for use in patients with asymptomatic severe aortic stenosis (AS). This groundbreaking approval marks the first-ever FDA authorization for TAVR in asymptomatic patients, potentially transforming the treatment landscape for those with this critical condition.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced its participation in the highly anticipated BofA Securities 2025 Health Care Conference, scheduled for Tuesday, May 13, 2025. The company's leadership, including CEO Bernard Zovighian and CFO Scott Ullem, will take part in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible to investors and healthcare professionals through a live webcast available on the Edwards Lifesciences investor relations website at http://ir.edwards.com. An archived version of the session will be accessible later in the day for those unable to attend the live event.

SHERIDAN, WYOMING – May 7, 2025 – A new randomized controlled trial (RCT) has revealed significant advancements in rotator cuff repair, showing that augmentation with the REGENETEN Bioinductive Implant can substantially reduce the risk of re-tears, offering hope for better outcomes in patients undergoing full-thickness rotator cuff repairs. The study's findings have the potential to set a new standard of care in orthopedic surgery.

Understanding the Challenge of Rotator Cuff Repairs

Rotator cuff repairs are among the most commonly performed orthopedic procedures, with an estimated 750,000 surgeries taking place annually in the United States alone. However, the procedure is not without its challenges, as up to 25% of patients experience re-tears, often leading to additional treatments and prolonged recovery times.

SHERIDAN, WYOMING – May 7, 2025 – The growing prevalence of rotator cuff tears, coupled with increasing patient expectations, has sparked a reevaluation of traditional surgical approaches. With more than 750,000 rotator cuff repairs performed annually in the U.S. and the number rising steadily, it’s clear that surgical interventions must evolve to meet the challenges of faster recovery times, improved functional outcomes, and better patient satisfaction. The latest advancements, particularly bioinductive repair using the REGENETEN Bioinductive Implant, present promising alternatives to the established methods of rotator cuff surgery.

SHERIDAN, WYOMING – May 6, 2025 – Zimmer Biomet Holdings, Inc., a global leader in medical technology, has officially launched the "You’ll Be Back" campaign, led by their Chief Movement Officer, Arnold Schwarzenegger. The campaign aims to support millions of individuals suffering from joint pain by offering a unique online community. This initiative seeks to empower people with the knowledge and resources they need to make informed decisions about their mobility and overall health.

The "You’ll Be Back" campaign invites those experiencing limited mobility due to joint pain in areas such as the hip, knee, and shoulder to share their personal stories, join a supportive community, and connect with qualified physicians. Schwarzenegger, an advocate for fitness and mobility, has committed to driving this movement by personally reading submitted stories and selecting participants for a motivational docuseries.

SHERIDAN, WYOMING – May 6, 2025 – The healthcare industry has long relied on traditional training methods for healthcare professionals (HCPs), but recent challenges highlighted by the COVID-19 pandemic have underscored the urgent need for innovation in medical education. Enter Virtual Reality (VR), a transformative tool that is revolutionizing the way healthcare workers are trained and empowering them to deliver better care while improving patient outcomes.

As hospitals and medical institutions continue to face staffing shortages, burnout, and the need for enhanced medical education, VR is emerging as a solution that can help fill critical gaps. By offering immersive, repeatable training experiences, VR technology provides healthcare workers with the opportunity to develop and refine their skills, all while alleviating some of the pressure on experienced professionals and offering tangible benefits to patients.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the induction of Eric Diebold, Ph.D., Vice President and General Manager of Instruments, Software, and Informatics, Biosciences, to the prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. This distinction, awarded to individuals who have made pioneering contributions to the field, underscores the significant role that Diebold has played in advancing medical and biological engineering, particularly in the realms of photonics, high-speed imaging, and flow cytometry.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its participation in the upcoming Bank of America Securities Health Care Conference, scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time. The live webcast of the presentation will be available on the BD investor relations website, with a replay accessible afterward for those unable to attend the live event.

BD’s Commitment to Innovation in Health Care

BD continues to lead the charge in transforming the medical technology landscape. With a vast portfolio of cutting-edge solutions, BD plays a critical role in advancing medical discovery, diagnostics, and the delivery of care. Through its presentation at the prestigious Bank of America Securities Health Care Conference, BD aims to further demonstrate how its innovations enhance the safety, efficiency, and quality of care for both patients and healthcare providers.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, has announced its fiscal 2025 second-quarter financial results, highlighting strategic investments and operational resilience despite a challenging macroeconomic environment. The company reported a revenue increase of 4.5% year-over-year, driven by organic growth, currency-neutral revenues, and a focus on operational efficiency.

BD's continued commitment to innovation and market leadership is evident as it invests in manufacturing capacity and product advancements across its key segments. This article delves into the company’s financial performance, strategic initiatives, and future growth outlook, underlining its position as a driving force in the global healthcare market.

SHERIDAN, WYOMING – May 6, 2025 – Stryker (NYSE: SYK), a leading innovator in medical technology, has announced its participation in the highly anticipated Bank of America Securities 2025 Global Healthcare Conference. The event will take place on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. The company’s presentation, set for 1:40 p.m. Pacific Time, will be delivered by Preston Wells, Vice President and Chief Financial Officer, alongside Jason Beach, Vice President, Finance and Investor Relations.

As a global leader in the medical technology sector, Stryker continues to play a pivotal role in shaping the future of healthcare. This participation in the Bank of America Securities 2025 Global Healthcare Conference marks a significant opportunity for the company to showcase its strategic initiatives, innovations, and contributions to improving healthcare outcomes worldwide.

Key Presentation Highlights

SHERIDAN, WYOMING – May 6, 2025 – Stryker Corporation (NYSE: SYK) has announced its operating results for the first quarter of 2025, showing significant growth in both reported and organic sales, underscoring the company’s strong market performance. The global leader in medical technology posted a notable 11.9% increase in net sales, achieving $5.9 billion, with organic sales growth reaching 10.1%.

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.

Double-Digit Revenue Growth Across Segments and Regions

Boston Scientific achieved broad-based momentum across its business units and global markets:

• MedSurg segment delivered 11.7% reported growth (12.8% operational, 5.3% organic).
• Cardiovascular segment saw standout performance with 26.2% reported growth (27.6% operational, 25.6% organic).

Regional growth highlights included: